Evidence map›Paper›PMID 38918602›Full record

ArticleNature aging2024

Age differentially impacts adaptive immune responses induced by adenoviral versus mRNA vaccines against COVID-19.

Beatrice Dallan, Davide Proietto, Martina De Laurentis, Eleonora Gallerani, Mara Martino, Sara Ghisellini, Amedeo Zurlo, Stefano Volpato, Benedetta Govoni, Michela Borghesi and 17 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. The ageing immune system and its battle with viruses.The Journal of general virology · 2026
    Review
  6. Article
  7. Immunology of RNA-based vaccines: The critical interplay between inflammation and expression.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Beatrice Dallan *Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy.
Davide Proietto *Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy.
Martina De LaurentisDepartment of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy.
Eleonora GalleraniDepartment of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy.
Mara MartinoDepartment of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy.
Sara GhiselliniLaboratory of Clinical Pathology, University Hospital St. Anna, Ferrara, Italy.
Amedeo ZurloDepartment of Medical Sciences, University of Ferrara, Geriatrics Unit, University Hospital of Ferrara, Ferrara, Italy.
Stefano VolpatoDepartment of Medical Sciences, University of Ferrara, Geriatrics Unit, University Hospital of Ferrara, Ferrara, Italy.
Benedetta GovoniDepartment of Medical Sciences, University of Ferrara, Geriatrics Unit, University Hospital of Ferrara, Ferrara, Italy.
Michela BorghesiDepartment of Economics and Management, University of Ferrara, Ferrara, Italy.
Valentina AlbaneseDepartment of Environmental and Prevention Sciences, University of Ferrara, Ferrara, Italy.ORCID http://orcid.org/0000-0002-1947-2644
Victor AppayUniversité de Bordeaux, CNRS UMR 5164, INSERM ERL 1303, ImmunoConcEpT, Bordeaux, France.ORCID http://orcid.org/0000-0001-5434-3963
Stefano BonniniDepartment of Economics and Management, University of Ferrara, Ferrara, Italy.
Sian Llewellyn-LaceyDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.
Salvatore PacificoDepartment of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy.
Laura GrumiroDepartment of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Martina BrandoliniDepartment of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Simona SempriniUnit of Microbiology, Greater Romagna Area Hub Laboratory, Cesena, Italy.
Vittorio SambriDepartment of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Kristin LadellDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.ORCID http://orcid.org/0000-0002-9856-2938
Helen M ParryInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.ORCID http://orcid.org/0000-0002-9707-8167
Paul A H MossInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.ORCID http://orcid.org/0000-0002-6895-1967
David A PriceDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.ORCID http://orcid.org/0000-0001-9416-2737
RIV Study Group
Antonella CaputoDepartment of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy.
Riccardo GavioliDepartment of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy.
Francesco NicoliDepartment of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy. francesco.nicoli@unife.it.ORCID http://orcid.org/0000-0001-6327-5958

Funding

DH | National Institute for Health Research (NIHR) COV-LT2-0041Medical Research Council MC_PC_20060Medical Research Council MR/V028448/1
6 · The paper itself

Abstract

Adenoviral and mRNA vaccines encoding the viral spike (S) protein have been deployed globally to contain severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Older individuals are particularly vulnerable to severe infection, probably reflecting age-related changes in the immune system, which can also compromise vaccine efficacy. It is nonetheless unclear to what extent different vaccine platforms are impacted by immunosenescence. Here, we evaluated S protein-specific immune responses elicited by vaccination with two doses of BNT162b2 or ChAdOx1-S and subsequently boosted with a single dose of BNT162b2 or mRNA-1273, comparing age-stratified participants with no evidence of previous infection with SARS-CoV-2. We found that aging profoundly compromised S protein-specific IgG titers and further limited S protein-specific CD4

Indexed as

2019-nCoV Vaccine mRNA-1273Adaptive ImmunityBNT162 VaccineCOVID-19COVID-19 VaccinesmRNA VaccinesSARS-CoV-2Spike Glycoprotein, CoronavirusAdenovirus VaccinesAdultAgedAge FactorsAgingAntibodies, ViralCD4-Positive T-LymphocytesCD8-Positive T-Lymphocytes2019-nCoV Vaccine mRNA-1273Adenovirus VaccinesAntibodies, ViralBNT162 VaccineChAdOx1 nCoV-19COVID-19 VaccinesmRNA VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, Synthetic

Identifiers

PMID38918602

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.